"It is positive that we continue to attract new customers and grow in today's economic climate. Despite the challenging economic situation, the demand for our non-animal GARD® tests remains strong, with more world-leading customers than ever before using the GARD® platform. We also see growth in the demand for efficacy testing for customers in the pharmaceutical and cosmetic industries, while orders from medical device customers have been temporarily affected by delays in the new medical device regulations (MDR). Considering the high level of interest and the large number of quotations we have outstanding, we believe the company will continue to develop positively," says Peter Nählstedt, President and CEO.
The sales of GARD® continue to grow steadily with new and recurring major global customers in the cosmetics, chemical, and medical device sectors. The customer base expanded with nine new customers during the quarter, and by the end of September, 25 new customers had been added in 2023, compared to 18 for the entire year 2022. This was achieved while sales from existing customers accounted for 90 percent of the total. Recurring sales included a larger testing assignment with the
The growing interest in GARD® is also reflected in our sales through distributors, which increased significantly after the
Sales through our subsidiaries in
By controlling costs and increasing sales to maintained margins, the company is progressing towards reaching break-even.
These sales figures have not been audited by an auditor, they should not be interpreted as meaning that profitability has been achieved, and they are subject to change at the time of the half-yearly financial statements. The Company chose to report these figures to provide shareholders with relevant information.
Invitation to presentation/webcast on
SenzaGen’s President and CEO
Time: At 09:05 on
Registration: https://www.biostock.se/en/biostocklifesciencesummit/
© Modular Finance, source